Leukemia Clinical Trials

A listing of Leukemia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 231 clinical trials
Study of Magrolimab Combinations in Participants With Myeloid Malignancies

The primary objectives of this study are to evaluate the safety, tolerability and to determine the recommended Phase 2 dose (RP2D) of magrolimab (Mag) in combination with the anti-leukemia

  • 0 views
  • 12 Jan, 2022
  • 8 locations
  • 0 views
  • 15 Jan, 2022
  • 33 locations
Infusion of Donor Derived Cytokine Induced Killer (CIK) Cells in Hematological Patients Relapsed After Haploidentical Stem Cell Transplant

, possess the characteristics of both T cells and Natural Killer (NK) and show in vivo a very strong cytolytic activity against leukemia, but a low reactivity against the host. Therefore, this study has as

  • 0 views
  • 01 Jan, 2022
  • 1 location
Safety and Efficacy of ThisCART19 in Patients With Refractory or Relapsed B Cell Malignancies

This is a study to evaluate the safety and clinical activity of ThisCART19 (Allogeneic CAR-T targeting CD19) in patients with refractory or relapsed CD19 positive B cell malignancies.

  • 0 views
  • 17 Jan, 2022
  • 3 locations
Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia (ISAKIDS)

Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Acute Myeloid Leukemia (AML) Secondary Objectives: Safety and tolerability assessments Assessment of infusion

idarubicin
mitoxantrone
minimal residual disease
cytarabine
residual tumor
  • 0 views
  • 23 Jan, 2022
  • 57 locations
A Study of JNJ-75276617 in Participants With Acute Leukemia

The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D[s]) of JNJ-75276617 in Part 1 (Dose Escalation) and to determine safety and tolerability at the RP2D(s) in Part 2 (Dose Expansion).

acute leukemia
hydroxyurea
gilbert's syndrome
direct bilirubin
serum bilirubin level
  • 4 views
  • 09 Jan, 2022
  • 27 locations
A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients

This study will explore 2 different doses of inotuzumab ozogamicin including the dose that is approved and a lower dose. The main purpose of this study is to evaluate whether a dose of inotuzumab ozogamicin, lower than the approved dose, could be recommended for adult patient with relapsed or refractory …

cancer
blast cells
induction chemotherapy
kinase inhibitor
lymphoid leukemia
  • 181 views
  • 19 Jan, 2022
  • 44 locations
Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia (TUD-APOLLO-064)

Acute promyelocytic leukemia (APL) is a rare subtype of acute myeloid leukemia (AML) characterized by consistent clinical, morphologic, and genetic features. According to the FAB classification

acute promyelocytic leukemia
idarubicin
secondary mds
mitoxantrone
cytarabine
  • 0 views
  • 26 Jan, 2022
  • 7 locations
Study to Evaluate the Safety and Efficacy of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Previously Untreated Adults With TP53 Mutant Acute Myeloid Leukemia

The primary objective of this study is to compare the efficacy of magrolimab + azacitidine versus venetoclax + azacitidine in adults with previously untreated TP53 mutant acute myeloid leukemia

azacitidine
idarubicin
TP53
cytarabine
daunorubicin
  • 0 views
  • 08 Jan, 2022
  • 16 locations
A Study of Oral Venetoclax Tablets and Oral Azacitidine Versus Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy

This study will be conducted in two parts. Part 1 will be the Dose Confirmation portion to determine recommended Phase 3 dose (RPTD) of venetoclax in combination with AZA. Part 3 will be conducted in 2 phases - Dose Finding portion to determine RPTD of venetoclax in combination with CC-486 …

azacitidine
cancer
consolidation chemotherapies
venetoclax
remission
  • 41 views
  • 07 Jan, 2022
  • 332 locations